Anne Whitaker appointed to the Board as NED
10/06/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220610:nRSJ3983Oa&default-theme=true
RNS Number : 3983O Ergomed plc 10 June 2022
PRESS RELEASE
Anne Whitaker appointed to the Board as Non-Executive Director
Guildford, UK - 10 June 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, today announces that Anne Whitaker will join the
Board as an independent Non-Executive Director following the Company's AGM
later today, 10 June 2022.
Anne Whitaker has extensive life sciences industry experience, having worked
across the pharmaceutical, biotech and specialty pharma sectors for the last
thirty years in the US and internationally. Anne previously held a number of
senior executive roles at Sanofi, GlaxoSmithKline, Bausch Health Company and
Synta Pharmaceuticals, and most recently, she held the position of Chief
Executive Officer, and subsequently Chairperson of Aerami Therapeutics, a
private life science company. She has served as a Non-Executive Director at a
number of UK-listed healthcare / pharmaceutical services companies including
UDG Healthcare and Vectura Group and is currently on the board of a number of
global biopharmaceutical companies.
Anne is recognised as a biopharma industry influencer, advisor and leader,
having received numerous awards from PharmaVoice, WomenInc and Fierce Pharma.
She holds a BSc in Chemistry and Business from the University of North
Alabama.
Dr. Miroslav Reljanović, Executive Chairman of Ergomed, commented: "Anne has
an excellent track record and extensive global pharmaceutical industry
experience and we are delighted to have her joining the Board. I believe that
her global network and deep understanding of the pharmaceutical services
industry will support the continued growth and strategic development of
Ergomed's CRO and PV businesses internationally."
Anne Whitaker, incoming Non-Executive Director, said: "I have witnessed
Ergomed's consistent growth in recent years and I am highly excited to be
joining a leading provider of specialised services to the pharmaceutical
industry. I look forward to working with the Board to continue Ergomed's
growth trajectory as we support customers and patients around the world."
Additional Disclosures
The following information regarding the appointment of Anne Michelle Clem
Whitaker, aged 55, is disclosed under Schedule 2(g) of the AIM Rules for
Companies:
Current directorships and/or partnerships: Former directorships and/or partnerships (within the last five years):
Aerami Therapeutics Holdings, Inc. Chason Dreams, LLC
Anne Whitaker Group, LLC Cree, Inc.
Bryn Pharma LLC ECR Pharmaceuticals Co., Inc.
Caladrius Biosciences, Inc. KNOW Bio, LLC
Curio Digital Therapeutics, Inc. UDG Healthcare, Plc
Faron Pharmaceuticals Oy Vast Therapeutics Inc.
Mallinckrodt Plc* Vectura Group Limited
Nykode Therapeutics ASA Wolfspeed, Inc.
OraSure Technologies Inc.
Trinity Life Sciences
Ms Whitaker does not have any beneficial interest in the ordinary shares of
the Company.
*Mallinckrodt plc filed for bankruptcy in October 2020 while facing class
action litigation.
Save as set out above, no further information regarding Anne Whitaker is
required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM
Rules for Companies.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis (Nominated Adviser and Joint Broker) Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP (Joint Broker) Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher
Golden
Consilium Strategic Communications - for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal / Angela Gray ergomed@consilium-comms.com (mailto:ergomed@consilium-comms.com)
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAFLFLAREIAIIF